Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Announces $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Fulcrum Therapeutics from Outperform to Market Perform, setting a price target of $4.
September 12, 2024 | 7:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leerink Partners has downgraded Fulcrum Therapeutics from Outperform to Market Perform, with a new price target of $4, indicating a less optimistic outlook.
The downgrade from Outperform to Market Perform by Leerink Partners suggests a less favorable view on Fulcrum Therapeutics' stock performance. The $4 price target indicates a potential downside, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100